HighTower Advisors
MITO

HighTower Advisors’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

HighTower Advisors’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-56,000
Closed -$14K – 3495
2022
Q2 		$14K Buy
+56,000
New +$19.3K ﹤0.01% 3043

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HighTower Advisors's MITO Position: Q3 2022 in Review

HighTower Advisors sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2022, closing a stake of 56,000 shares — an estimated $14K sold.

HighTower Advisors first reported a position in MITO in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 12 funds tracked by Wall St. Rank hold MITO as of Q3 2022.

  • HighTower Advisors reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2022 after selling out during the quarter.
  • HighTower Advisors sold 56,000 Stealth BioTherapeutics Corp. ADS shares in Q3 2022, an estimated $14K.
  • HighTower Advisors first reported a position in Stealth BioTherapeutics Corp. ADS in Q2 2022 and held it in 1 quarter.
  • HighTower Advisors's Stealth BioTherapeutics Corp. ADS position peaked at $14K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2022.

Based on HighTower Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.